Classical and Paradoxical Effects of TNF-α on Bone Homeostasis.
Osta B, Benedetti G, Miossec P. · 2014
Read Classical and Paradoxical Effects of TNF-α on Bone Homeostasis. by Osta B, Benedetti G, Miossec P. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3923157.txt.
Introduction
Bilal Osta, Giulia Benedetti, and Pierre Miossec review the double-edged role of the immune signal TNF-alpha in bone balance, in Frontiers in Immunology in 2014. TNF blockers have greatly helped patients with inflammatory joint disease, yet the exact pathways by which this signal steers bone remodeling are still unclear. Bone is constantly built by osteoblasts and broken down by osteoclasts, and TNF touches both sides.
The classic picture casts TNF as a blocker of bone building and a driver of bone breakdown. Newer work shows it can also spur bone building, depending on dose, exposure time, and the cell's state. The review pulls together evidence from single cells, whole bones, and whole bodies, then applies it to rheumatoid arthritis and ankylosing spondylitis, two diseases with opposite bone problems.
Catalog record
| CREATOR | Osta B, Benedetti G, Miossec P. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Classical and Paradoxical Effects of TNF-α on Bone Homeostasis By Bilal Osta, Giulia Benedetti, Pierre Miossec Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2014.00048 ABSTRACT Tumor necrosis factor-α (TNF-α) plays an essential role in the regulation of bone homeostasis in several chronic immune and inflammatory joint diseases, where inhibition of TNF has led to significant clinical improvement. However, TNF-activated pathways and mechanisms involved in bone remodeling remain unclear. So far, TNF-α was known as an inhibitor of osteoblast differentiation and an activator of osteoclastogenesis. Recent contradictory findings indicated that TNF-α can also activate osteoblastogenesis. The paradoxical role of TNF-α in bone homeostasis seems to depend on the concentration and the differentiation state of the cell type used as well as on the exposure time. This review aims to summarize the recent contradictory findings on the regulation of bone homeostasis by TNF-α at the isolated cell, whole bone, and whole body levels. In addition, the involvement of TNF-α in the bone remodeling imbalance is observed in inflammatory joint diseases including rheumatoid arthritis and ankylosing spondylitis, which are associated with bone destruction and ectopic calcified matrix formation, respectively. Both diseases are associated with systemic/vertebral osteoporosis. INTRODUCTION Tumor necrosis factor-α (TNF-α) is one of the several pro-inflammatory cytokines involved in bone remodeling. Classically, TNF-α plays a major role in the regulation of bone homeostasis by stimulating osteoclastogenesis and inhibiting osteoblast (OB) function. It is also involved in the pathogenesis of chronic inflammation in both mouse and human models. Based on these observations, treatments of several chronic inflammatory diseases such as Crohn’s disease, ulcerative colitis, and psoriasis target TNF-α. TNF-α is also associated with the pathogenesis of inflammatory joint diseases including rheumatoid arthritis (RA), which is characterized by massive juxta-articular bone destruction, and ankylosing spondylitis (AS), which is characterized by simultaneous bone destruction and excessive formation, respectively. However, opposite findings suggest that TNF-α may also induce osteogenic differentiation. This review summarizes the classical and paradoxical effects of TNF-α on bone homeostasis by focusing on osteoblastogenesis and osteoclastogenesis. TNF-Α AND ITS SIGNALING PATHWAYS The immune response is modulated by several inflammatory cytokines including TNF-α. TNF-α acts through several pathways including the activation of nuclear factor kappa-B (NF-κB) involved in inflammation and apoptosis (1). TNF-α is produced mainly by monocytes, but can also be secreted by many other cell types (1–3). It is produced as a transmembrane protein (mTNF-α) that is subsequently cleaved by the TNF-α converting enzyme (TACE) to a soluble form (sTNF-α) (4). Both types are biologically active and bind as a trimer to either TNF receptors TNFR1 (also known as TNFRSF1A or p55) or to TNFR2 (also known as TNFRSF1B or p75). Activation of TNFR1 death domain initiates the apoptotic signaling through the activation of several factors such as caspase and NF-κB resulting in transcription of pro-inflammatory cytokines, chemokines, and anti-apoptotic molecules (5). Unlike TNFR1, the cell expression of TNFR2 is far more limited and does not contain a death domain. Its effects include T cell activation and proliferation via signaling pathways that involve NF-κB, activator protein 1 (AP-1), and the mitogen-activated protein kinases (MAPKs) (6). The pro-inflammatory effects of this cytokine are well documented (7) and are involved in many osteo-immunological diseases including RA and AS (8). In humans, TNF-α antagonists are clearly effective in a large number of conditions, as first shown in patients with RA (9, 10). However, incidents of lupus-like syndrome and skin lesions have been reported in patients receiving anti-TNF therapies (11). The cellular and molecular mechanisms underlying the TNF-α-mediated pro-inflammatory effects and the occasionally paradoxical effects of TNF-α antagonists in chronic inflammatory diseases remain incompletely understood (10). This also applies to bone biology. BONE BIOLOGY Bone structure is affected by several paracrine and endocrine factors including mechanical abrasion and serum electrolyte levels such as calcium and phosphorus. This remodeling is regulated by several cells such as osteoclasts (OCs), OBs, and osteocytes (OYs) (12). This continuous remodeling prevents and removes fatigue-related micro-damage and allows adaptation of the bone mass and structure. The number and activity of OCs and OBs are determined by a multitude of factors such as hormones, cytokines, and locally produced signaling molecules under the influence of mechanical stimuli (13–15). Among these factors, TNF-α was found to have great effects on both bone regulator cells, OBs and OCs. Biology of osteoclasts Osteoclasts are hematopoietic cells derived from the monocyte lineage. They undergo a series of differentiation steps to become mature bone-resorbing cells. Intracellular signaling cascade of transcriptional regulation of osteoclast-specific genes is activated by macrophage-colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL) (16) (Figure 1). Upon differentiation, OC precursor cells express strongly RANK, the receptor for RANKL. [Figure: Role of TNF-α in osteoclast differentiation. Hematopoietic stem cells differentiate along the myelo-monocytic pathway with M-CSF stimulation. Differentiating cells continue along a trajectory toward the osteoclast phenotype under the influence of RANKL, which signals through the transcription factors AP-1 and NF-κB. In the presence of RANKL, various pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1, cooperatively orchestrate enhanced osteoclastogenesis. TNF-α signals via NF-κB and the mitogen-activated protein kinases (MAPKs), and IL-6 via the JAK–STAT pathway. The activation of osteoclasts with the inflammatory mechanisms mentioned leads to exaggerated systemic and local bone loss. [AKT, protein kinase B; CA2, carbonic anhydrase 2; CSK, cathepsin K; ERK, extracellular signal-regulated kinase; IKK, IκB kinase; JAK, janus kinase; gp130, glycoprotein 130; GRB2, growth factor receptor-bound protein 2; MITF, microphthalmia-associated transcription factor; MMP, matrix metalloproteinase; NFATc1, nuclear factor of activated T-cells, cytoplasmic 1; PI3K, phosphoinositide 3-kinase; SPI1, spleen focus forming virus (SFFV) proviral integration oncogene spi1; STAT, signal transducer and activator of transcription; TRAP, tartrate-resistant acid phosphatase].] Biology of osteoblasts Osteoblasts are derived from pluripotent stem cells called “mesenchymal stem cells (MSCs)” capable of differentiating into adipocytes, chondrocytes, fibroblasts, skeletal muscle cells, and tendon cells (17). A number of factors can stimulate the differentiation toward an osteoblastic direction. The first step includes the proliferation of osteoprogenitors leading to the production of proteins such as histones, fibronectin, and type I collagen. Subsequently, osteogenic matrix is formed through the expression of genes responsible for the production of alkaline phosphatase (ALP), bone sialoprotein, and type I collagen. Finally, extracellular matrix is mineralized by activation of genes involved in the release of osteocalcin (OCN), osteopontin, and collagenase. This complex cascade of gene expression and cellular differentiation is orchestrated by several transcription factors including the runt-related transcription factor-2 (Runx2) and surface expression of RANKL (Figure 2A). [Figure: Tumor necrosis factor-α and its osteoblastogenesis paradoxical effects. (A) Under normal condition, various receptors and downstream signaling pathways can be activated in osteoblasts. The most common ligands, receptors, and their signal transduction are represented in black. Essential pathways involve bone morphogenetic proteins (BMPs) and their receptors, acting via SMAD proteins to directly or transcriptionally activate RUNX2 and its subsequent downstream cellular events and the Wnt–frizzled pathway, which utilizes β-catenin for further activities. Under inflammatory conditions, the release of pro-inflammatory cytokines such as TNF-α and IL-6 leads to the inhibition of osteogenic differentiation via several mechanisms (represented in green in the figure). IL-6 inhibits mitogen-activated protein kinase (MAPK) activities by activated signal transducers and activators of transcription (STAT). TNF-α activates SMAD ubiquitination regulatory factor-1 (SMURF1) and SMURF2 leading to the inhibition